STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

October 1, 2024

Study Completion Date

March 31, 2025

Conditions
Cancer-associated ThrombosisThrombocytopenia
Interventions
BIOLOGICAL

Enoxaparin

"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation"

BIOLOGICAL

Dalteparin

"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation"

BIOLOGICAL

Tinzaparin

"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation"

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

University of Alberta, Edmonton

K1H 8L6

RECRUITING

The Ottawa Hospital, Ottawa

N8W 1L9

RECRUITING

Windsor Regional Hospital, Windsor

All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER